Research programme: monoclonal antibody 1F7 - Immune Network/InNexus Biotechnology

Drug Profile

Research programme: monoclonal antibody 1F7 - Immune Network/InNexus Biotechnology

Alternative Names: 1F7

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Developer Immune Network; InNexus Biotechnology
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 14 Jun 2002 InNexus has acquired a sublicense from Immune Network to develop monoclonal antibody1F7
  • 25 Jan 2002 Immune Network has entered into a research collaboration with the University of British Columbia
  • 16 Jan 2002 A study has been added to the Viral Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top